These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10318765)

  • 21. Proxy activation of protein ErbB2 by heterologous ligands implies a heterotetrameric mode of receptor tyrosine kinase interaction.
    Huang GC; Ouyang X; Epstein RJ
    Biochem J; 1998 Apr; 331 ( Pt 1)(Pt 1):113-9. PubMed ID: 9512468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
    Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of ErbB2 in Corneal Epithelial Wound Healing.
    Xu KP; Riggs A; Ding Y; Yu FS
    Invest Ophthalmol Vis Sci; 2004 Dec; 45(12):4277-83. PubMed ID: 15557433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression.
    Anderson NG; Ahmad T; Chan K; Dobson R; Bundred NJ
    Int J Cancer; 2001 Dec; 94(6):774-82. PubMed ID: 11745477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidermal growth factor (EGF) receptor kinase-independent signaling by EGF.
    Deb TB; Su L; Wong L; Bonvini E; Wells A; David M; Johnson GR
    J Biol Chem; 2001 May; 276(18):15554-60. PubMed ID: 11279155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
    Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
    Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
    Xu W; Yuan X; Jung YJ; Yang Y; Basso A; Rosen N; Chung EJ; Trepel J; Neckers L
    Cancer Res; 2003 Nov; 63(22):7777-84. PubMed ID: 14633703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth hormone-induced phosphorylation of epidermal growth factor (EGF) receptor in 3T3-F442A cells. Modulation of EGF-induced trafficking and signaling.
    Huang Y; Kim SO; Jiang J; Frank SJ
    J Biol Chem; 2003 May; 278(21):18902-13. PubMed ID: 12642595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distribution of resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living cells using number and brightness analysis.
    Nagy P; Claus J; Jovin TM; Arndt-Jovin DJ
    Proc Natl Acad Sci U S A; 2010 Sep; 107(38):16524-9. PubMed ID: 20813958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
    Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor.
    Alvarado D; Klein DE; Lemmon MA
    Nature; 2009 Sep; 461(7261):287-91. PubMed ID: 19718021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
    Stoica GE; Franke TF; Moroni M; Mueller S; Morgan E; Iann MC; Winder AD; Reiter R; Wellstein A; Martin MB; Stoica A
    Oncogene; 2003 Sep; 22(39):7998-8011. PubMed ID: 12970748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
    Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.
    Xia W; Liu LH; Ho P; Spector NL
    Oncogene; 2004 Jan; 23(3):646-53. PubMed ID: 14737100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns.
    Wosikowski K; Schuurhuis D; Johnson K; Paull KD; Myers TG; Weinstein JN; Bates SE
    J Natl Cancer Inst; 1997 Oct; 89(20):1505-15. PubMed ID: 9337347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation.
    Wang Z; Zhang L; Yeung TK; Chen X
    Mol Biol Cell; 1999 May; 10(5):1621-36. PubMed ID: 10233167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitation of the effect of ErbB2 on epidermal growth factor receptor binding and dimerization.
    Li Y; Macdonald-Obermann J; Westfall C; Piwnica-Worms D; Pike LJ
    J Biol Chem; 2012 Sep; 287(37):31116-25. PubMed ID: 22822073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.